Venkateswaran C Pillai1, Kelong Han2, Richard H Beigi3, Gary D Hankins4, Shannon Clark4, Mary F Hebert5, Thomas R Easterling5, Anne Zajicek6, Zhaoxia Ren6, Steve N Caritis3, Raman Venkataramanan1. 1. Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, PA. 2. Clinical Pharmacology, Genentech, Inc, CA. 3. Department of Obstetrics, Gynecology and Reproductive Sciences, Magee-Women's Hospital, University of Pittsburgh Medical Center, PA. 4. Department of Obstetrics and Gynecology, University of Texas Medical Branch, TX. 5. Department of Pharmacy and Obstetrics & Gynecology, University of Washington, WA. 6. Obstetric and Pediatric Pharmacology and Therapeutics Branch, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, MD, USA.
Abstract
AIMS: Physiological changes in pregnancy are expected to alter the pharmacokinetics of various drugs. The objective of this study was to evaluate systematically the pharmacokinetics of oseltamivir (OS), a drug used in the treatment of influenza during pregnancy. METHODS: A multicentre steady-state pharmacokinetic study of OS was performed in 35 non-pregnant and 29 pregnant women. Plasma concentration-time profiles were analyzed using both non-compartmental and population pharmacokinetic modelling (pop PK) and simulation approaches. A one compartment population pharmacokinetic model with first order absorption and elimination adequately described the pharmacokinetics of OS. RESULTS: The systemic exposure of oseltamivir carboxylate (OC, active metabolite of OS) was reduced approximately 30 (19-36)% (P < 0.001) in pregnant women. Pregnancy significantly (P < 0.001) influenced the clearance (CL/F) and volume of distribution (V/F) of OC. Both non-compartmental and population pharmacokinetic approaches documented approximately 45 (23-62)% increase in clearance (CL/F) of OC during pregnancy. CONCLUSION: Based on the decrease in exposure of the active metabolite, the currently recommended doses of OS may need to be increased modestly in pregnant women in order to achieve comparable exposure with that of non-pregnant women.
AIMS: Physiological changes in pregnancy are expected to alter the pharmacokinetics of various drugs. The objective of this study was to evaluate systematically the pharmacokinetics of oseltamivir (OS), a drug used in the treatment of influenza during pregnancy. METHODS: A multicentre steady-state pharmacokinetic study of OS was performed in 35 non-pregnant and 29 pregnant women. Plasma concentration-time profiles were analyzed using both non-compartmental and population pharmacokinetic modelling (pop PK) and simulation approaches. A one compartment population pharmacokinetic model with first order absorption and elimination adequately described the pharmacokinetics of OS. RESULTS: The systemic exposure of oseltamivir carboxylate (OC, active metabolite of OS) was reduced approximately 30 (19-36)% (P < 0.001) in pregnant women. Pregnancy significantly (P < 0.001) influenced the clearance (CL/F) and volume of distribution (V/F) of OC. Both non-compartmental and population pharmacokinetic approaches documented approximately 45 (23-62)% increase in clearance (CL/F) of OC during pregnancy. CONCLUSION: Based on the decrease in exposure of the active metabolite, the currently recommended doses of OS may need to be increased modestly in pregnant women in order to achieve comparable exposure with that of non-pregnant women.
Authors: Laura G Greer; Richard D Leff; Vanessa Laibl Rogers; Scott W Roberts; George H McCracken; George D Wendel; Jeanne S Sheffield Journal: Am J Obstet Gynecol Date: 2011-03-09 Impact factor: 8.661
Authors: Ingrid Cardenas; Robert E Means; Paulomi Aldo; Kaori Koga; Sabine M Lang; Carmen J Booth; Carmen Booth; Alejandro Manzur; Enrique Oyarzun; Roberto Romero; Gil Mor Journal: J Immunol Date: 2010-06-16 Impact factor: 5.422
Authors: Mohamed A Kamal; Scott A Van Wart; Craig R Rayner; Vishak Subramoney; Daniel K Reynolds; Catharine C Bulik; Patrick F Smith; Sujata M Bhavnani; Paul G Ambrose; Alan Forrest Journal: Antimicrob Agents Chemother Date: 2013-05-13 Impact factor: 5.191
Authors: C R Rayner; C C Bulik; M A Kamal; D K Reynolds; S Toovey; J P Hammel; P F Smith; S M Bhavnani; S A Van Wart; P G Ambrose; A Forrest Journal: Antimicrob Agents Chemother Date: 2013-05-13 Impact factor: 5.191
Authors: Timothy M Uyeki; Henry H Bernstein; John S Bradley; Janet A Englund; Thomas M File; Alicia M Fry; Stefan Gravenstein; Frederick G Hayden; Scott A Harper; Jon Mark Hirshon; Michael G Ison; B Lynn Johnston; Shandra L Knight; Allison McGeer; Laura E Riley; Cameron R Wolfe; Paul E Alexander; Andrew T Pavia Journal: Clin Infect Dis Date: 2019-03-05 Impact factor: 9.079
Authors: Mohamed A Kamal; Patrick F Smith; Nathorn Chaiyakunapruk; David B C Wu; Chayanin Pratoomsoot; Kenneth K C Lee; Huey Yi Chong; Richard E Nelson; Keith Nieforth; Georgina Dall; Stephen Toovey; David C M Kong; Aaron Kamauu; Carl M Kirkpatrick; Craig R Rayner Journal: Br J Clin Pharmacol Date: 2017-02-20 Impact factor: 4.335